Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.93 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.93 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.93 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cobicistat SCHEMBL2736227 | 0.96 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| Cobicistat SCHEMBL2736053 | 0.96 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| Cobicistat SCHEMBL10201697 | 0.96 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| Cobicistat SCHEMBL10201695 | 0.96 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| Cobicistat SCHEMBL16632480 | 0.96 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL18159507 | 0.94 | CYP3A4 (0.95) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL20674820 | 0.94 | CYP3A4 (0.94) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL23678770 | 0.94 | CYP3A4 (0.94) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL13267635 | 0.93 | CYP3A4 (0.90) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL16137143 | 0.92 | CYP3A4 (0.89) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030043-A1 | NOVEL PROCESS FOR THE PREPARATION OF 1,3-THIAZOL-5-YLMETHYL [(2R,5R)-5- CARBAMOYL) AMINO] -4-(MORPHOLIN-4-YL)BUTANOYL]AMINO}-1,6-DIPHENYLHEXAN-2-YL]CARBAMATE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-02-01 | — | — | US | disclosed |
| US-20170056423-A1 | COMBINATION THERAPY COMPRISING TENOFOVIR ALAFENAMIDE HEMIFUMARATE AND COBICISTAT FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030043-A1 | NOVEL PROCESS FOR THE PREPARATION OF 1,3-THIAZOL-5-YLMETHYL [(2R,5R)-5- CARBAMOYL) AMINO] -4-(MORPHOLIN-4-YL)BUTANOYL]AMINO}-1,6-DIPHENYLHEXAN-2-YL]CARBAMATE | CPS1, METTL3, ACMSD | CYP3A4 633/4885CYP2D6 871/4885CYP2C9 747/4885 |
| US-20170056423-A1 | COMBINATION THERAPY COMPRISING TENOFOVIR ALAFENAMIDE HEMIFUMARATE AND COBICISTAT FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | MTAP, PAICS, GART | CYP3A4 304/4885CYP2D6 909/4885CYP2C9 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.